NEW YORK (Reuters Health)—Eruptive keatoacanthomas and extensive panniculitus are among the dermatological conditions associated with the anticancer agent pembrolizumab, researchers say. Pembrolizumab, a humanized IgG4 PD-1 (programmed cell death-1) antagonist antibody, is an immune checkpoint inhibitor (CPI) approved in the U.S. for treating advanced melanoma, non-small-cell lung cancer and head and neck squamous cell carcinoma….